Hypoxia-targeted car-t cells for advanced gastric cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new type of immunotherapy called CAR-T cells that are designed to seek out and kill cancer cells in the low-oxygen environment of tumors. It is for people with advanced stomach cancer that has not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced stomach cancer that cannot be removed by surgery and has not responded to standard therapy, or you choose not to have standard therapy.
- Your tumor must have high levels of two proteins called AXL and CD73 (a special test will check this).
- You are well enough to perform daily activities (ECOG score 0 or 1).
- You have at least one measurable tumor (1 cm or larger).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a freezing technique (cryoablation) combined with an immunotherapy drug (PD-1 inhibitor) for people with advanced stomach cancer that has spread or cannot be removed by surgery. It's for those whose cancer has continued to grow after one or two types of chemotherapy.
This trial tests a new type of immune cell therapy called CBG131 CAR-T cells for people with advanced stomach or pancreatic cancer that has stopped responding to standard treatments. The therapy targets a protein called CLDN18.2 on cancer cells, and the study aims to see if it can shrink tumors.
This trial tests a new type of cell therapy (CAR-NK cells) designed to attack gastric and esophageal junction cancers that have specific markers on their surface. The cells are engineered to recognize two targets on your cancer cells, which may help your immune system fight the cancer more effectively.
This trial tests an experimental therapy for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments. The therapy targets a specific protein (CLDN18.2) found on cancer cells. The goal is to see if this approach can help control the disease.
This trial tests a new treatment combining an injection (XH001) with specially made immune cells (T-cells) that target your tumor's unique markers. It's for people with advanced stomach cancer who have not responded to standard therapies.
This trial tests a new type of CAR-T cell therapy designed to target two proteins, CD73 and AXL, found on cancer cells. It is for people with advanced or metastatic solid tumors (like bile duct, pancreatic, lung, breast, head and neck, or gynecologic cancers) who have not responded to standard treatment or have no standard first-line therapy available.
Hear when a new Stage IV Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.